Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole
Clinical and Translational Science · 2024
DOI: 10.1111/cts.13887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von Sylvia D Klomp und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Inflammation, Antifungal Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health~Holland, Stichting LSH-TKI.
Abstract (Originalsprache)
Voriconazole is the cornerstone of the treatment and prevention of fungal infections. While there is a good correlation between CYP2C19 genotype and voriconazole exposure during prophylactic treatment, no correlation was found in patients with invasive aspergillosis. Proinflammatory cytokines result in inhibition of CYP2C19 enzyme activity (and may result in phenoconversion). Here we investigated the relationship between inflammation, CYP2C19 genotype‐predicted‐phenotype, and CYP2C19 activity in patients receiving voriconazole. Data were obtained from two prospective studies investigating voriconazole treatment (NCT02074462 and NCT00893555). Dose‐corrected voriconazole plasma concentration and C‐reactive protein (CRP) were used as proxies for CYP2C19 activity and inflammation, respectively. After data extraction and synthesis, data from 39 patients with paired voriconazole and CRP measurements were available. The distribution of CYP2C19 genotype‐predicted metabolizer phenotypes was 31% intermediate (IM), 41% normal (NM), and 28% rapid metabolizer (RM). During inflammation, dose‐corrected voriconazole levels were increased by 245%, 278%, and 486% for CYP2C19 NMs IMs and RMs, respectively. Patients with moderate or high CRP levels (>50 mg/L) were phenoconverted to a lower metabolizer phenotype irrespective of their CYP2C19 genotype. In a subgroup analysis of eight patients with longitudinal data available with and without inflammation, the pattern of the dose‐corrected voriconazole and CRP measurements were similar, with CYP2C19 activity following decreasing or increasing CRP levels. In conclusion, voriconazole plasma concentrations increase during inflammation due to downregulation of CYP2C19 activity. While this effect appears largest for CYP2C19 RMs, no clinically relevant differences were observed between the CYP2C19 genotypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy & Toxicology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.
- Apotheek, OLVG, Amsterdam, The Netherlands.
- Faculty of Medicine and Health, Sydney School of Pharmacy, Sydney, New South Wales, Australia.
- The University of Sydney Institute for Infectious Diseases, Sydney, New South Wales, Australia.
- Westmead Hospital, Sydney, New South Wales, Australia.
ORCID-Profile: Sylvia D Klomp, Anette Veringa, Jan-Willem C Alffenaar, Mark G J de Boer, Lambert F R Span, Henk-Jan Guchelaar, Jesse J Swen
Förderung
- Health~Holland, Stichting LSH-TKI
Zitieren
APA
Klomp, S. D., Veringa, A., Alffenaar, J. C., de Boer, M. G. J., Span, L. F. R., Guchelaar, H. J., & Swen, J. J. (2024). Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and Translational Science. https://doi.org/10.1111/cts.13887
Vancouver
Klomp SD, Veringa A, Alffenaar JC, de Boer MGJ, Span LFR, Guchelaar HJ, et al. Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole. Clinical and Translational Science. 2024. doi:10.1111/cts.13887
BibTeX
@article{Klomp2024,
author = {Klomp, Sylvia D and Veringa, Anette and Alffenaar, Jan-Willem C and de Boer, Mark G J and Span, Lambert F R and Guchelaar, Henk-Jan and Swen, Jesse J},
title = {Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.13887}
}
EUVIMED